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What’s already known about this topic?  
 Perceived stigmatization is common and distressing in patients with psoriasis. Some 
of its predictors have been examined in small samples. 
 
What does this study add? 
 This large study of 514 patients with psoriasis examined a combination of potential 
predictors variables, both previously examined and never before studied. 
 Sociodemographic, disease-related, and never before studied Type D personality 
variables were found to be predictive of perceived stigmatization.  
 These results provide an understanding of which patients may be especially 
vulnerable to stigmatization-related problems, which may warrant special attention 
during treatment. 
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SUMMARY 
 
Background: The physical appearance of psoriasis can be cosmetically disfiguring, resulting 
in a substantial social burden for patients. An important aspect of this burden is the 
experience of stigmatization. While stigmatization is known to be disabling and stressful for 
patients, little is known about its correlates and effective interventions are lacking.  
Objectives: To examine predictor variables for perceived stigmatization in psoriasis.  
Methods : Questionnaires were administered to 514 patients with psoriasis in a cross-
sectional study and zero-order correlational and multiple regression analyses were conducted 
including sociodemographic, disease-related, personality, illness cognitions, and social 
support predictor variables. 
Results: Stigmatization was experienced by 73% of patients to some degree, and correlated 
with all five categories of predictor variables. In multiple regression analyses, stigmatization 
was associated with higher impact on daily life, lower education, higher disease visibility, 
severity, and duration, higher levels of social inhibition, having a Type D personality, and not 
having a partner. 
Conclusions: Results indicate that perceived stigmatization is common in psoriasis, and can 
be predicted by sociodemographic, disease-related, and personality variables. These predictor 
variables provide indications on which patients are especially vulnerable regarding perceived 
stigmatization, which might be used in treatment.  
 
Keywords: stigmatization, psoriasis, chronic skin conditions, predictors, personality 
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INTRODUCTION 
It has long been theorised that humans have a fundamental need to be accepted by others and 
included in social interactions.1 Social relationships are important for health and wellbeing, 
and social rejection can lead to physical, behavioural, and emotional problems.1 Social 
rejection is central to the experience of stigmatization, which can be defined as an awareness 
of social disapproval, discrediting, or devaluation based on an attribute or physical mark.2,3  
In psoriasis, a chronic skin condition characterised by red plaques on the skin4, the 
experience of stigmatization is commonly mentioned as one of its more troubling 
characteristics.5-9 Patients often experience felt or perceived stigma, referring to the negative 
attitudes and responses that they perceive to be present in society and the sense of shame and 
fear of being discriminated against because of being ‘flawed’ due to their illness.10,11 Actual 
experiences of stigmatization (i.e., enacted stigma) are also reported; for instance, reactions 
of disgust or aversion, negative comments, or avoidance of contact.7,9 Stigmatization 
contributes considerably to disability, depression, and reduced quality of life in psoriasis12-14, 
and can be considered a stressor. As distress can be a trigger for psoriasis exacerbation, this 
can become a vicious self-perpetuating cycle.15-17 
 Despite these detrimental consequences, relatively few studies have studied 
interventions targeting stigmatization-related problems and thus far no compelling evidence 
has been found for any type of intervention.18,19 Firstly, it is important to recognise that 
stigmatization is a societal problem, and therefore societal educational interventions 
including contact between patients and the general population are called for to alter the public 
view.20 Furthermore, interventions with a more inter- and intrapersonal focus are needed to 
improve patients’ ability to cope with perceived stigmatization. In order to aid intervention 
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development, a broad understanding of associated risk factors is needed, to be able to identify 
risk populations and focus points for interventions. 
The literature suggests several potential sociodemographic predictors of perceived 
stigmatization in psoriasis, such as lower age7, being female5, and lower education.7 
Secondly, disease-related variables such as higher disease severity, longer disease duration, 
greater cosmetic involvement, and greater impact of the condition on daily life may be 
relevant.7-9,13,21,22 General ways in which patients deal with a chronic condition, such as 
heightened helplessness regarding the disease and its consequences, and lower disease 
acceptance have also been found to be predictive.7 Additionally, social support and a large 
social network may serve a protective function against experiences of stigmatization.7 
While several studies have examined the abovementioned variables as predictors, the 
role of personality has hardly been studied.7,9 A possibly relevant personality construct is 
Type D, which is defined as a tendency to inhibit the expression of emotions or behaviour to 
avoid negative reactions of others (social inhibition; SI), in combination with the stable 
tendency to experience negative affect (negative affectivity; NA).23 Type D has been 
associated with increased risk of cardiovascular morbidity and mortality24 and impaired 
health behaviour25, which are both frequently reported in psoriasis.26,27 The two main features 
SI and NA may both increase the impact of perceived stigmatization. Being socially inhibited 
implies being sensitive to negative reactions of others, which may cause stigmatization 
experiences to be especially detrimental. Additionally, having a stable tendency to experience 
negative affect may worsen psychological distress, which in turn may increase disease 
severity and resultantly visibility15-17, and thereby vulnerability to stigmatization experiences. 
Furthermore, individuals with high levels of NA may be more likely to perceive social 
interactions as negative, due to the associated cognitive bias to negative information.28 The 
specific combination of heightened SI and NA, Type D, has mainly been related to adverse 
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outcomes in cardiovascular patients24,29-31, but also to poorer physical, psychological, and 
social functioning in other healthy and patient samples32,33, including two studies in 
psoriasis.34,35 
This study aims to examine the relative contributions of a broad range of concepts, 
including never examined variables such as Type D personality, to perceived stigmatization 
in a large sample of patients with psoriasis. It was hypothesised that perceived stigmatization 
would be related to the sociodemographic variables age, educational level, and being single; 
the disease-related variables severity, duration, visibility, and impact; Type D personality; the 
illness cognitions acceptance and helplessness; and social support. This broad approach may 
provide indications for screening and interventions for reducing stigmatization-related 
problems.  
 
MATERIALS AND METHODS 
 
Participants  
Psoriasis patients were recruited from one academic and three non-academic hospitals, and 
the Dutch Psoriasis Association. Inclusion criteria were a minimum age of 18 years and a 
dermatologist-confirmed psoriasis diagnosis. Exclusion criteria were illiteracy, pregnancy, 
and severe physical and mental comorbid conditions. This study made use of questionnaires 
that were administered between 2010 and 2013 to determine participant eligibility for a study 
on the effectiveness of internet-based cognitive behavioural treatment for psoriasis (van 
Beugen et al., submitted). Parts of these data have been used in a previous paper.36 All 
questionnaires were assessed prior to the intervention. The study was approved by the 
regional medical ethics committee and carried out in accordance with the declaration of 
Helsinki.37 All participants provided informed consent.  
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Measures 
Perceived stigmatization was measured with a 6- item subscale of the Impact of Chronic Skin 
Disease on Daily Life questionnaire (ISDL38; Cronbach’s α in this study=.88), assessing to 
what extent the patient feels stigmatized as a result of the skin condition. Items are assessed 
on a 4-point Likert scale, with higher scores reflecting higher levels of perceived 
stigmatization (theoretical range=6-24). Example items are “Others feel uncomfortable 
touching me due to my skin disease” or “Other people sometimes make annoying comments 
about my skin disease”.  
 
To assess predictor variables, the following measures were used: 
 
1) Sociodemographic variables 
Sociodemographic variables were assessed with a general checklist that assessed patients’ 
gender, age, educational level, and marital status. Educational level was categorised into 
primary (i.e., lower education, elementary school), secondary (i.e., middle school, high 
school, including vocational training) and tertiary (i.e., higher professional education and 
university- level education). 
 
 
2) Disease-related variables 
Self-assessed disease severity was measured with the Self-Administered Psoriasis Area and 
Severity Index (SAPASI39,40, theoretical range=0-72). Self-assessed disease visibility was 
measured with a 4-items ISDL subscale38 asking about the extent of involvement of the face, 
scalp, neck, and hands (theoretical range=4-16). Disease duration was assessed by asking 
how old the patient was when diagnosed, and subtracting this number from their current age 
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(range=0-64). Impact of the disease on daily life was assessed with a 10- item ISDL 
subscale38, assessing the extent that the skin condition affects daily life activities (theoretical 
range = 10-40, α=.89).  
 
3) Personality 
The Type D scale 14 (DS1441) was used to assess Type D personality. It consist of two 7- item 
subscales; social inhibition (α=.88, example item: “I often feel inhibited in social 
interactions”, theoretical range = 0-28) and negative affectivity (α=.89, example item: “I often 
feel unhappy”, theoretical range=0-28). A cutoff score of ≥10 on both scales is used  to 
classify Type D personality. Using these cutoff scores, one in four participants in this study 
(25.1%) had a Type D personality. As previous studies indicate that Type D is best 
represented as a continuous variable42,43 the interaction term between the NA and SI 
subscales was used as a measure of Type D.  
  
4) Illness cognitions 
The Illness Cognition Questionnaire (ICQ44) was used to measure two illness cognitions: 
acceptance, assessing the extent of positive adaptation to chronic illness with emphasis on 
decreasing its negative aspects (6 items, α=.88, theoretical range=6-24) and helplessness, 
assessing the extent to which patients concentrate on aversive aspects of the disease (6 items, 
α=.88, theoretical range=6-24). 
 
5) Social support  
Social support was assessed with a 5-item ISDL subscale38, assessing the qualitative aspect of 
social support (α=.86, theoretical range=5-20), and the quantitative aspect, asking patients 
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about the actual size of their social network (range=0-25). This score was categorised 
according to norm groups38. 
 
Statistical analysis 
All variables were checked for outliers, normality and normal distribution of residuals, and  
logarithmic transformations were successfully applied in case of non-normal distribution of 
variables (i.e., perceived stigmatization, helplessness and disease severity). Winsorizing was 
applied in outlying SAPASI scores prior to log-transformation, limiting the influence of 
extreme values. Zero-order correlations between perceived stigmatization and predictor 
variables were examined by Pearson correlation coefficients for continuous variables, and t-
tests and ANOVAs for categorical variables. Zero-order correlations were interpreted as 
small (r=.10-.29), moderate (r=.30-.49), or large (r≥ .50).45 Only study variables showing 
significant zero-order correlations with perceived stigmatization were entered in regression 
analyses. To study the relative contribution of five categories of variables (sociodemographic, 
disease-related, personality, illness cognitions, and social support), each category was entered 
in a consecutive step with perceived stigmatization as the dependent variable. Only 
statistically significant individual predictor variables (p<.05) were retained in further models. 
For Type D, main effects of mean-centered NA and SI were first examined and in a second 
block their interaction term was added. All regression analyses were conducted with SPSS 
21.0 on a dataset without missing values (n=433). 
Results 
Sample characteristics 
Sociodemographic characteristics of the study sample (n=514) and means and SDs of study 
variables can be found in Tables 1 and 2. Disease severity was generally mild to moderate, 
with 6.7% of patients having severe psoriasis (i.e., SAPASI >10).46 Means on perceived 
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stigmatization, impact on daily life, social support, and illness cognitions were similar to 
those found in previous research in psoriasise.g.38, and scores on Type D personality were 
comparable to those found in the general population.33,47  
Perceived stigmatization 
Seventy-three percent of our sample perceived at least some stigmatization, as indicated by a 
positive score on at least 1 of the 6 items, as reported in previous studies.7,8 The feeling of 
being stared at was reported most often (in 61.9% of patients), followed by other people 
thinking their condition was contageous (44.9%), finding them unattractive because of their 
skin condition (38.1%), avoiding to touch them (32.3%), and making negative comments 
(27.7%). 
 
Individual associations with perceived stigmatization  
 
Zero-order correlations of study variables are reported in Table 3. Higher perceived 
stigmatization showed a large correlation with a greater impact of the skin condition on daily 
life; moderate correlations with higher disease severity, helplessness, and NA, and lower 
levels of acceptance; and small correlations with a lower age, a longer disease duration, 
greater visibility, higher levels of SI, and less perceived social support. Furthermore, higher 
perceived stigmatization scores were associated with a smaller social network (p=.001), not 
having a partner (p<.001), and a lower educational level (p=.01), but not with gender 
(p=1.00). 
 
Relative impact on perceived stigmatization 
Table 4 presents results of multiple regression analyses that were performed to examine the 
relative impact of predictors on perceived stigmatization. 
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In block 1, sociodemographic variables explained 11.9% of the variance in perceived 
stigmatization, with lower age, lower education, and being singe being predictive of higher 
levels of perceived stigmatization. In block 2, adding the disease-related variables explained a 
total of 48.3% of the variance, with greater disease severity and visibility, longer disease 
duration, and a higher disease impact predicting more perceived stigmatization. In block 3, 
adding the personality variables resulted in a total of 49.7% explained variance, with the main 
effect of SI (but not NA) and the Type D interaction effect being predictive of perceived 
stigmatization. Patients scoring both high on SI and NA, indicating a Type D personality, had 
higher levels of perceived stigmatization (Fig. 1). In blocks 4 and 5, illness cognitions of 
helplessness and acceptance, and perceived and actual social support did not significantly add 
to the model.  
The final model, including only the significant predictors, explained a total of 49.7% 
of the variance in perceived stigmatization (Table 5). Predictors, from highest to lowest 
standardised regression coefficients, were a higher disease impact, lower age, lower 
education and greater disease visibility, higher disease severity and longer disease duration, 
higher levels of SI, having a Type D personality, and being single. A model excluding 
multivariate outliers (n=16; critical Mahalanobis Distance value=32.91, df=12, p=.001) 
yielded similar results, with the exception of two predictors that became marginally 
significant (Type D personality, p=.08) or non-significant (marital status, p=.11).  
 
DISCUSSION 
This study examined perceived stigmatization and its potential sociodemographic, disease-
related, and psychosocial predictors in a large sample of patients with psoriasis. The vast 
majority of our sample experienced perceived stigmatization to some degree, corresponding 
with previous studies.e.g.7,8 Higher levels of perceived stigmatization were found to be 
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correlated with sociodemographic and disease-related variables, personality, illness 
cognitions, and social support. Perceived stigmatization was found to be particularly 
predicted by disease impact as well as by lower age, lower education, greater disease severity 
and visibility, longer disease duration, higher levels of SI, having a Type D personality, and 
being single.  
 Greater severity and visibility and longer disease duration were predictive of 
perceived stigmatization, underlining the importance of early dermatological treatment; 
patients whose psoriasis is not adequately controlled may be more affected by stigmatization. 
However, the impact of the condition was a much stronger predictor, corresponding with the 
notion that the subjective experience of impact is generally more important than disease 
severity.e.g.48,49 In contrast with an earlier study7, the impact of the condition was also a 
stronger predictor than the illness cognition of helplessness. The relative and different 
contribution of both variables may be explained by the high correlation between these 
variables in the current study and in previous research.48 It seems likely that patients with 
psoriasis who are prone to feelings of helplessness regarding the disease may also experience 
a larger impact of psoriasis and magnify negative reactions of others.  
 Type D personality and its subcomponent SI were found to be significant predictors of 
perceived stigmatization. The fear of disapproval that leads individuals to inhibit emotions or 
behaviour in SI41 may explain its relation to perceived stigmatization; socially inhibited 
individuals may be more sensitive to the reactions of others and may therefore perceive 
themselves to be stigmatized more readily. Not only SI in itself, but also the combination of 
higher levels of SI and NA, Type D personality, was a significant predictor of perceived 
stigmatization. This corresponds with studies suggesting that Type D is associated with social 
impairments.50,51 These results extend preliminary evidence indicating that Type D may be a 
risk factor for worse outcomes in psoriasis34,35, by showing for the first time that it is 
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associated with increased perceived stigmatization. However, these results should be 
replicated in further research, as the effect of Type D became marginally significant when 
excluding multivariate outliers. In the current study, NA was not a significant predictor of 
perceived stigmatization. It seems that, while the shared variance with NA can also be 
explained by other variables, SI contains more unique information relevant for perceived 
stigmatization. 
Regarding sociodemographic variables, the significant predictors lower age, lower 
educational level and being single were in line with previous research indicating that the 
negative psychosocial influence of psoriasis is particularly strong in younger patients.e.g.7,52 
To develop a comprehensive model of factors influencing perceived stigmatization, 
both potential risk factors (e.g., social fears and inhibition) and protective factors (e.g., social 
support) need to be taken into account. While the current study provides evidence for the 
former, results of the latter (social support) were inconsistent with previous research7, 
possibly due to the inclusion of predictor variables not previously studied. Furthermore, while 
the current study examined self-perceived support, a more objective measure may lead to 
different results. Nonetheless, current results suggest that it is not so much the experienced 
social support that plays a significant role in perceived stigmatization, but more the extent to 
which patients may experience social anxiety and want to avoid negative reactions, as 
captured in SI. Future research should further explore the role of protective factors in 
perceived stigmatization. 
Strengths of the current study include the large sample size, simultaneous assessment 
of relevant variables to control for shared variance, including personality variables never 
before studied, and inclusion of patients from a variety of settings. Limitation include the 
cross-sectional design, precluding conclusions about cause and effect, and the relatively mild 
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disease severity of our sample, which may limit generalizability. In addition, self-report 
measures were used to assess disease severity. However, self-assessed PASI scores correlate 
reasonably well with clinician-assessed PASI scores39,53 and modest relationships with 
stigmatization have also been found in studies using the clinician-assessed PASI.54,55 Lastly, 
some predictor variables showed high intercorrelations, but none of them were above the 
multicollinearity cutoff point of .80.56 
In conclusion, perceived stigmatization was found to be common in patients with 
psoriasis and was predicted by specific sociodemographic, disease-related, and personality 
variables. This provides several possible focus points for individual screening and 
interventions, in addition to the societal interventions that are needed to target the 
overarching problem. Firstly, the predictors found in this study provide clinicians with an 
understanding of which patients may be especially vulnerable to stigmatization-related 
problems, which may warrant special attention during consultations. Type D and especially 
its social inhibition component may be screened for, when further evidence confirms our 
preliminary results indicating that individuals with this personality subtype are especially 
vulnerable to stigmatization-related problems. Stigmatization-related problems may be 
screened using validated instruments38, followed by targeted interventions that may focus on 
the impact of the condition on daily life, considering that this was the largest predictor. 
Cognitive behavioural treatment, including social skills training, seems promising as an 
intervention framework. Previous research indicates that it can decrease perceived 
stigmatization in skin conditions57, improve psychological and disease-related outcomes in 
psoriasis58,59, and decrease helplessness, which shows high correlations with disease 
impact.60-62 In order to target the social inhibition aspect of Type D personality, social skills 
training and evidence-based interventions for social fears, such as cognitive behavioural 
therapy and/or exposure therapy, may be an additional treatment approach.63,64 
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The current study provides a framework of characteristics of patients who are at 
greater risk to perceive stigmatization, which has been shown to have detrimental 
psychological consequences in psoriasis. Future research should expand upon these findings 
in order to examine interplays between predictors in prospective studies. Further development 
of screening and intervention procedures are needed in order to facilitate implementation of 
tailored evidence-based treatment to reduce the psychosocial burden of chronic skin 
conditions. 
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Table 1. Sociodemographic characteristics of study sample (n=514) 
Characteristic Mean SD (range) 
Age (years) 52.21 13.00 (18-84) 
 N % 
Gender   
   Male 286 55.6 
   Female 228 44.4 
Marital status   
   Unmarried 62 12.1 
   Married/living together 410 79.8 
   Divorced 24 4.7 
   Widowed 18 3.5 
Educational status   
   Primary 16 3.1 
   Secondary 306 59.5 
   Tertiary 190 37.0 
 Missing 2 0.4 
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Table 2. Means and standard deviations of study variables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
an = 489; bn = 498. 
 
 
Characteristic Mean ± SD  Range 
 
Perceived stigmatization 9.02 ± 3.48 6-24 
Disease-related    
  Disease severitya 5.09 ± 4.02 0-33 
  Disease visibility 1.85 ± 0.57 1.0-3.5 
  Disease duration (years)b 15.72 ± 14.75 0-62 
  Impact on daily life 16.06 ± 6.06 10-40 
Type D (n, %)  129 25.1 
  Negative affectivity (NA) 8.45 ± 6.02 0-26 
  Social inhibition (SI)  9.13 ± 6.01 0.27 
Illness cognitions   
  Helplessness 9.38 ±3.74 6-24 
  Acceptance 17.19 ±4.46 6-24 
Social Support   
  Perceived support 15.80 ±3.60 5-20 
  Actual support 8.12 ±5.33 0-25 
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Table 3. Zero-order correlation matrix of continuous study variables 
 
 
Variable  1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1.  Stigmatization   -           
2.  Age  -.28*** -          
3.  Disease severity  .34*** -.14** -         
4.  Disease visibility  .26*** -.12** .29*** -        
5.  Disease duration  .13** .22*** .11* -.03 -       
6.  Disease impact  .61*** -.17*** .32*** .26*** .11* -      
7.  Type D: NA  .30*** -.23*** .20*** .12* -.05 .36*** -     
8.  Type D: SI  .22*** -.11* .05 .07 -.03 .17*** .41*** -    
9.  Helplessness  .49*** -.09# .28*** .19*** .10* .67*** .39*** .17*** -   
10. Acceptance  -.34*** .10* -.19*** -.23*** .10* -.48*** -.42*** -.20*** -.52*** -  
11. Perceived support  -.16*** -.02 .02 .00 .00 -.18*** -.36*** -.27*** -.17*** .26*** - 
 
Note. NA = Negative Affectivity; SI = Social Inhibition. 
 *p<.05 **p<.01 ***p<.001 #p<.10. 
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Table 4. Predictors of stigmatization: multiple regression analyses 
 
Predictors Standardised regression coefficients (β) 
 Block 1 Block 2 Block 3 Block 4 Block 5 
Sociodemographic      
Age -.27*** -.19*** -.19*** -.19*** -.18*** 
Education (primarya) .06 .03 .03 .03 .02 
  Education (secondarya) .15** .12*** .12** .11** .11** 
Married / With partnerb -.13** -.07* -.07# -.07# -.06 
Disease-related       
Disease severity  .10** .10** .10* .11** 
Disease visibility  .12** .12** .12** .12** 
Disease duration  .11** .11** .11** .09* 
Impact on daily life  .51*** .50*** .46*** .50*** 
Personality      
  Negative affectivity (NA)  .00 -.01 -.02 
Social inhibition (SI)   .10** .10* .09* 
Type D personality 
(interaction NA*SI) 
  .08* .08* .07* 
Illness cognitions      
  Helplessness    .05  
  Acceptance    -.01  
Social support      
  Perceived support     -.03 
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 Actual support (1-4c)     -.15 
 Actual support (5-14c)     -.17 
 Actual support (15-25c)     -.13 
F-change 16.78*** 76.16*** 4.31** 0.44 0.63 
R2 .12 .48 .50 .50 .50 
 
Note. a Reference group = tertiary education; bReference group = no partner; cNumber of 
friends, reference group = no friends.  
 ***p<.001, **p<.01, *p<.05, #p<.10.  
 
Table 5. Predictors of stigmatization: final model 
 
Predictors β  B  SE 
Sociodemographic  
  Age -.19*** -.00***   (.00) 
Married / With partnera -.07# -.02#  (.01) 
Education (primary)b .04 .03 (.03) 
Education (secondary)b .12** .03** (.01) 
Disease-related   
  Disease severity .10* .02*  (.01) 
  Disease visibility .12** .03** (.01) 
  Disease duration .11** .00**  (.00) 
  Impact on daily life .50*** .01***  (.00) 
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Personality  
Negative affectivity .00 .00 (.01) 
Social inhibition .10** .01**  (.00) 
Type D .08* .01* (.00) 
F-change 37.80*** 
R2 .50 
 
Note. β = standardised coefficients, B = unstandardised coefficients, SE = standard error of B. 
a Reference group = no partner; bReference group = tertiary education.  
 ***p<.001 **p<.01 *p<.05. 
 
FIGURE LEGENDS 
 
Figure 1. Interaction effect of negative affectivity (NA) and social inhibition (SI) on 
perceived stigmatization. Predicted values of perceived stigmatization are displayed for high 
and low levels of NA and SI (i.e., 1 SD above/below the mean). For all other variables 
included in the model, mean scores were used to calculate the regression outcome. In this 
figure, the degree of SI was not associated with perceived stigmatization when patients had 
low NA. For patients high on NA, specifically the combination with high SI, indicating a 
Type D personality, was related to higher levels of perceived stigmatization.  
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